Precigen
56 articles with Precigen
-
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
3/29/2023
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase 1/1b dose escalation/dose expansion study (clinical trial identifier: NCT05694364) of PRGN-3007.
-
Precigen to Participate in a Virtual Fireside Chat at Cantor's The Future of Oncology Virtual Symposium
3/28/2023
Precigen, Inc. today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat on April 4, 2023 from 10:45 AM to 11:15 AM ET.
-
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
3/6/2023
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2022 financial results.
-
Precigen Announces Closing of Public Offering of Common Stock
1/27/2023
Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock.
-
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
1/25/2023
Precigen, Inc. announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share.
-
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock
1/24/2023
Precigen, Inc. announced it has commenced an underwritten public offering of $75.0 million of its common stock.
-
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
1/24/2023
Precigen, Inc. (Nasdaq: PGEN) today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).
-
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
1/11/2023
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference.
-
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
1/4/2023
Precigen, Inc. announced that the Company will host an investigator-led R&D event on January 24, 2023 at 4:30 PM ET to showcase the latest clinical advancements for the Company's investigational, first-in-class PRGN-2012 off-the-shelf AdenoVerse™ Immunotherapy in recurrent respiratory papillomatosis.
-
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/19/2022
Precigen, Inc. (Nasdaq: PGEN) today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PT/6:45 PM ET in San Francisco, California.
-
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
12/12/2022
Precigen, Inc. today presented positive Phase 1 dose escalation data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with r/r AML and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract# 4633).
-
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
11/9/2022
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2022 financial results and progress of clinical programs.
-
Precigen to Announce Third Quarter 2022 Financial Results on November 9th
11/2/2022
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release third quarter 2022 financial results after the market closes on Wednesday, November 9, 2022.
-
Precigen Names Rutul R. Shah Chief Operating Officer
9/21/2022
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R. Shah as the Company's Chief Operating Officer (COO), effective October 1, 2022.
-
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference
9/1/2022
Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference.
-
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
8/22/2022
Precigen, Inc. today announced that the Company has completed the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C.
-
Precigen Reports Second Quarter and First Half 2022 Financial Results
8/8/2022
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2022 financial results.
-
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
8/1/2022
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2022 financial results after the market closes on Monday, August 8, 2022.
-
As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.
-
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
7/5/2022
Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022.